Bannerbild German Brest Group

AURORA: inital results presented

07.05.2019

The initial results of AURORA were announced at the ESMO Breast Cancer Congress  in Berlin, Germany, by Dr Philippe Aftimos, Co-Principal Investigator of the programme and Clinical Trials Development Leader at the Jules Bordet Institute in Brussels, Belgium.

He presented the results for the first 381 patients included out of a planned total of 1,000. The researchers have identified molecular alterations present in excess in metastases that may be correlated with the spread of cancer and increased resistance to standard treatments.

Read the full press release by BIG.

News

  • 01.02.2019 Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

    Mehr ...
  • 18.01.2019 Prof. Loibl unter den meist zitierten Wissenschaftlern in 2018

    Prof. Dr. Sibylle Loibl gehört im Jahr 2018 mit Ihrer Arbeit im Bereich der Brustkrebsforschung zu den 1% der am meisten zitierten Wissenschaftlern.

    Mehr ...
  • 17.12.2018 Results of an interim analysis from KATHERINE trial

    We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

    Mehr ...
  • 16.12.2018 GBG-Jahrestreffen - Anmeldung möglich

    GBG-Jahrestreffen - Anmeldung möglich

    Die Anmeldung zum GBG Jahrestreffen, sowie zum AGO-Meeting 2019 in Frankfurt ist ab sofort möglich.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd